Alivus Life Sciences P/E Ratio
Current P/E Ratio
28.34
High Valuation
High - Growth expectations or overvalued
Alivus Life Sciences (ALIVUS) P/E ratio is 28.34 (High), EPS (TTM) ₹45.99, current price ₹1430.80 on NSE — High - Growth expectations or overvalued.
Current Valuation Metrics
P/E Ratio
28.34
Current Price
₹1430.80
EPS (TTM)
₹45.99
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.88
Sector Median
32.06
Sector Rank
#11 of 199
Sector Percentile
5.5%
ALIVUS P/E Ratio — Valuation Signal & Historical Context
Alivus Life Sciences P/E 28.34 — signal: Overvalued. Also explore ALIVUS stock price history to track price trends across different timeframes.
- Stock appears overvalued with PE of 28.34, suggesting caution for new investments
- Trading at discount to sector average PE of 56.88
ALIVUS vs Healthcare Peers — P/E Ratio Comparison
Alivus Life Sciences P/E 28.34 vs Healthcare average 56.88, median 32.06 — range 1.99–747.21.
Sector Average
56.88
Sector Median
32.06
Lowest P/E
1.99
Highest P/E
747.21
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |